Deals In Depth: December 2012
Executive Summary
Biogen and Isis teamed up in their third antisense deal. Baxter paid $4 billion for its partner, dialysis company Gambro. Biopharma financing was boosted by Amarin’s large debt offering and a couple $100 million-plus FOPOs. Volcano’s $445 million notes deal drove device fundraising to $604 million.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.